Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients With Advanced Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial   Positive high-level results from the TROPION-Lung01 Phase III trial showed that datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement for the dual primary endpoint of progression-free survival (..
Biopharma companies are increasingly becoming targets of ransomware attacks, with the number of breaches rising during the COVID-19 pandemic. Japanese company Eisai recently announced that it was hit by a ransomware attack, joining other pharmaceutical companies like Sun Pharmaceuticals, Novartis and AstraZeneca. According to Constella Intelligence, for the top 20 pharma companies, the total num..
AstraZeneca has partnered with Quell Therapeutics to develop cell therapies for Type 1 diabetes and inflammatory bowel disorder in a potential deal worth over $2 billion. The collaboration will involve the development of autologous multi-modular Treg cell therapies, which are designed to suppress an overactive immune response seen in organ transplantation, inflammatory and autoimmune disease. As..
AstraZeneca and Sanofi have received unanimous backing from the FDA’s Antimicrobial Drugs Advisory Committee for their respiratory syncytial virus (RSV) antibody, nirsevimab, for use in the pediatric setting. Nirsevimab is an investigational long-acting antibody that targets and binds to the part of the RSV virus that attaches to the host’s cells. If approved, nirsevimab would become the first i..
AstraZeneca has announced a partnership with Quell Therapeutics to develop cell therapies for Type 1 diabetes and inflammatory bowel disorder. The collaboration involves the use of Quell's T-regulatory (Treg) cell engineering toolbox to develop autologous multi-modular Treg cell therapies, which will be manufactured through to the end of the first-in-human clinical study. AstraZeneca has initial..
Pharmaceutical companies AstraZeneca and Sanofi have received unanimous approval from the FDA's Antimicrobial Drugs Advisory Committee for their respiratory syncytial virus (RSV) antibody, nirsevimab, to be used in pediatric settings. The committee voted 21-0 in favor of approving the immunizing antibody for use in infants during their first RSV season, while also recommending its approval for h..
AstraZeneca has teamed up with Quell Therapeutics to develop therapies for Type 1 diabetes and inflammatory bowel disorder, potentially putting over $2 billion on the line. AstraZeneca provided $85 million to get started, while the rest of the opportunity comes in the form of development and commercialization milestones and potential royalties down the line. Quell will be responsible for develop..
The American Society of Clinical Oncology (ASCO) conference showcased exciting new data for oncology treatments, with several drugs showing significant success rates. AstraZeneca's Tagrisso was found to outperform a placebo in trials for EGFR-mutated non-small cell lung cancer, Novartis' Kisqali impressed researchers with its ability to treat early breast cancer, and Merck's Keytruda was more ef..
